ETON Relative Valuation
ETON's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ETON is overvalued; if below, it's undervalued.
Historical Valuation
Eton Pharmaceuticals Inc (ETON) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of 23.77. The fair price of Eton Pharmaceuticals Inc (ETON) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 16.81 USD , Eton Pharmaceuticals Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：16.81
Fair
Undervalued
16.87
PE
1Y
3Y
5Y
Trailing
Forward
12.46
EV/EBITDA
Eton Pharmaceuticals Inc. (ETON) has a current EV/EBITDA of 12.46. The 5-year average EV/EBITDA is -90.24. The thresholds are as follows: Strongly Undervalued below -1044.62, Undervalued between -1044.62 and -567.43, Fairly Valued between 386.96 and -567.43, Overvalued between 386.96 and 864.15, and Strongly Overvalued above 864.15. The current Forward EV/EBITDA of 12.46 falls within the Historic Trend Line -Fairly Valued range.
17.89
EV/EBIT
Eton Pharmaceuticals Inc. (ETON) has a current EV/EBIT of 17.89. The 5-year average EV/EBIT is 686.06. The thresholds are as follows: Strongly Undervalued below -6804.34, Undervalued between -6804.34 and -3059.14, Fairly Valued between 4431.26 and -3059.14, Overvalued between 4431.26 and 8176.47, and Strongly Overvalued above 8176.47. The current Forward EV/EBIT of 17.89 falls within the Historic Trend Line -Fairly Valued range.
4.18
PS
Eton Pharmaceuticals Inc. (ETON) has a current PS of 4.18. The 5-year average PS is 3.84. The thresholds are as follows: Strongly Undervalued below -0.26, Undervalued between -0.26 and 1.79, Fairly Valued between 5.89 and 1.79, Overvalued between 5.89 and 7.94, and Strongly Overvalued above 7.94. The current Forward PS of 4.18 falls within the Historic Trend Line -Fairly Valued range.
23.05
P/OCF
Eton Pharmaceuticals Inc. (ETON) has a current P/OCF of 23.05. The 5-year average P/OCF is -6.68. The thresholds are as follows: Strongly Undervalued below -178.87, Undervalued between -178.87 and -92.78, Fairly Valued between 79.41 and -92.78, Overvalued between 79.41 and 165.51, and Strongly Overvalued above 165.51. The current Forward P/OCF of 23.05 falls within the Historic Trend Line -Fairly Valued range.
29.11
P/FCF
Eton Pharmaceuticals Inc. (ETON) has a current P/FCF of 29.11. The 5-year average P/FCF is 86.48. The thresholds are as follows: Strongly Undervalued below -753.18, Undervalued between -753.18 and -333.35, Fairly Valued between 506.31 and -333.35, Overvalued between 506.31 and 926.14, and Strongly Overvalued above 926.14. The current Forward P/FCF of 29.11 falls within the Historic Trend Line -Fairly Valued range.
Eton Pharmaceuticals Inc (ETON) has a current Price-to-Book (P/B) ratio of 19.49. Compared to its 3-year average P/B ratio of 11.70 , the current P/B ratio is approximately 66.65% higher. Relative to its 5-year average P/B ratio of 11.55, the current P/B ratio is about 68.80% higher. Eton Pharmaceuticals Inc (ETON) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 3.59%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -0.74% , the current FCF yield is about -100.00% lower.
19.49
P/B
Median3y
11.70
Median5y
11.55
4.75
FCF Yield
Median3y
3.59
Median5y
-0.74
Competitors Valuation Multiple
The average P/S ratio for ETON's competitors is 41.70, providing a benchmark for relative valuation. Eton Pharmaceuticals Inc Corp (ETON) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 117.54%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ETON increased by 26.20% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -25.98 to -64.96.
The secondary factor is the Revenue Growth, contributed 117.54%to the performance.
Overall, the performance of ETON in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Eton Pharmaceuticals Inc (ETON) currently overvalued or undervalued?
What is Eton Pharmaceuticals Inc (ETON) fair value?
How does ETON's valuation metrics compare to the industry average?
What is the current P/B ratio for Eton Pharmaceuticals Inc (ETON) as of Dec 05 2025?
What is the current FCF Yield for Eton Pharmaceuticals Inc (ETON) as of Dec 05 2025?
What is the current Forward P/E ratio for Eton Pharmaceuticals Inc (ETON) as of Dec 05 2025?